A. E. van der Bijl

The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination

L. B. S. Gelinck, A. E. van der Bijl, W.E.P. Beyer et al. · Annals of the Rheumatic Diseases · 2007 · 175 citations

Life Sciences, Immunology, Pharmacotherapy +17

Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis

A. E. van der Bijl, Y P M Goekoop-Ruiterman, Jeska K de Vries‐Bouwstra et al. · Arthritis & Rheumatism · 2007 · 122 citations

Medicine, Internal Medicine, Pharmacotherapy +13

Sustained Beneficial Effects of a Protocolized Treat‐to‐Target Strategy in Very Early Rheumatoid Arthritis: Three‐Year Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort

M. Vermeer, H. H. Kuper, Hein J. Bernelot Moens et al. · Arthritis Care & Research · 2013 · 85 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

A. E. van der Bijl, Ferdinand C. Breedveld, Christian Antoni et al. · Clinical Rheumatology · 2008 · 83 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +17

Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice

Geert A. A. Versteeg, Laura M. M. Steunebrink, Harald E. Vonkeman et al. · Clinical Rheumatology · 2018 · 72 citations · Full text

Medicine, Pharmacotherapy, End-of-life Care +14